
    
      The objective of this study is to analyze the selected wounds' natural history prior to
      including the selected wounds in the evaluation of safety and efficacy in Krystal Biotech's
      Phase III protocol of B-VEC.

      Subjects will be enrolled upon obtaining consent and meeting eligibility criteria.

      Patient Screening is done on-site, followed by the imaging of at least 1 wound, but up to 15
      wounds. All remaining imaging will be performed remotely with a smartphone or tablet
      application.

      Patients are on-trial for approximately four months.
    
  